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RVX-208 is an orally active small molecule that interacts selectively with the second ligand domain found in bromodomain extra-terminal 
proteins (BET). This interaction inhibits acetylated lysine, present in histones, from binding to the same site thus altering chromatin 
structure and in turn activity of selected genes. Previous studies showing increased production of ApoA-I the dominant protein in HDL 
involved epigenetic processes triggered by RVX-208 inhibition of BET. Recent analysis of pooled (6 month phase 2 studies; SUSTAIN 
& ASSURE, n=499) data gathered in these human trials of RVX-208 revealed a marked 55% (p=0.02) relative risk reduction (RRR) in 
MACE for the entire population with a more pronounced effect of -77% RRR (p=0.01) in those with diabetes mellitus (DM). Methods:  To 
understand how RVX-208 may reduce MACE, we examined >60 biomarkers in human trials and also in vitro microarray analysis. Results 
in rank order of significant changes between RVX-208 vs. placebo (change, p value) were; serum alkaline phosphatase (-6 U/L, <0.0001), 
HDL-c (+3 mg/dL, <0.001), ApoA-I (+7.5 mg/dL, <0.01), large HDL (+0.7 umol/L, <0.05), HDL size (+0.1, <0.05), and total HDL particles 
(+1.8 umol/L, <0.1). While these findings were evident in all patients, two groups appearing to benefit more from RVX-208 were those with 
DM or chronic kidney disease (CKD). In those with DM (n=192) given RVX-208 glucose was unchanged vs placebo rose +0.7 mmol/L, a 
non-significant difference (p<0.1). But in patients (n=119) with DM and HDL <40 mg/dL RVX-208 lowered glucose significantly (p<0.01) by 
-0.3 vs. +0.9 mmol/L in placebo. In CKD subjects (n=47) with eGFR <60 mL/min/1.73m2 given RVX-208 vs placebo there was a +3.4% 
vs. -5.9% in eGFR, respectively. Additionally microarray analysis of primary human hepatocytes mRNA following 3 or 48 hours of RVX-208 
(30 uM) treatment caused marked changes in pathways or networks such as; attenuation in inflammation, coagulation, complement and 
cholesterol synthesis. Summary: Thus selective BET inhibition using RVX-208 lowers serum ALP, alters HDL profile and pathways that may 
underlie lower MACE in all patients with high residual CVD risk but especially in such patients who also have DM or CKD.
